Wilson's T3 Weaning: How Research Subjects Taper Off the Protocol

The Wilson's WT3 protocol is not designed to be permanent. From the beginning, the protocol's framework treats exogenous T3 as a temporary intervention - a structured input that suppresses the hypothalamic-pituitary-thyroid (HPT) axis long enough to clear the reverse T3 accumulation and reset the metabolic thermostat. The endpoint is not stabilized exogenous T3 use; it is a recovered endogenous system that no longer needs it.

Weaning, or tapering, is therefore the intended conclusion of every successful Wilson's protocol cycle. A research subject who has reached and held the temperature target has done the hard part. The taper phase is where that achievement is tested: can the HPT axis resume adequate endogenous T3 production on its own, without the exogenous input that has been sustaining body temperature for weeks?

The research community has developed a defined taper framework for this transition. It mirrors the up-titration schedule in structure, uses the same 7.5 mcg step increments, and is governed by the same temperature monitoring that drove the escalation phase. When the taper goes cleanly, it is not a dramatic event - body temperature holds near the achieved set point as doses drop, and eventually the subject is off entirely, with their own system maintaining the temperature that previously required external support. When the taper reveals incomplete HPT axis recovery, that too is useful data that informs next steps.

This post reviews the completion criterion, the taper schedule, pharmacokinetic considerations, monitoring practices, and the post-protocol recovery patterns discussed in the research community.

Research framing. This article reviews Wilson's WT3 protocol weaning from a research-context standpoint. All compounds discussed are sold strictly for laboratory research and not for human consumption. See our FAQ on research legality for full terms.

The Completion Criterion: 98.6°F Sustained for 3 Weeks

The Wilson's protocol framework specifies a single primary completion criterion before initiating the taper: sustained average oral body temperature of 98.6°F (37.0°C) across multiple daily measurements for three consecutive weeks.

This threshold is specific for several reasons. The temperature target of 98.6°F represents the metabolic set point associated with normal cellular enzyme function, adequate thermogenesis, and a body temperature that is self-sustaining without constant exogenous T3 support. Values below this - even values that have risen substantially from a pre-protocol baseline - indicate that the metabolic thermostat has not fully reset. Initiating a taper before reaching sustained 98.6°F risks abandoning the protocol at a point where the underlying reverse T3 dominance has been partially, but not fully, cleared.

The three-week duration of sustained target temperature is the more demanding component of the criterion. Many research subjects transiently reach 98.6°F during the titration phase - the dose is climbing, T3 is rising, and temperature follows. The question is not whether 98.6°F can be reached with sufficient exogenous T3 input, but whether the metabolic system has genuinely recalibrated at that set point. Three consecutive weeks of sustained target temperature is the research-community-established threshold for confirming that the initial transient response has converted into a stable recalibration.

To measure this reliably, research subjects take oral temperature readings at three timepoints daily - typically mid-morning, mid-afternoon, and early evening - away from recent eating, drinking, or physical activity. The daily average across these three readings is the tracking metric. Three consecutive weeks of daily averages at or above 98.6°F, without significant dips below that threshold at individual readings, constitutes the completion criterion.

Subjects who reach 98.6°F and hold it for one to two weeks but then see temperatures begin to slip should not initiate the taper. The slip indicates that either the HPT axis is beginning to compensate against the exogenous T3 input or that reverse T3 is re-accumulating. The appropriate response is to hold the current dose, assess whether a dose adjustment is warranted, and restart the three-week stable-temperature clock only after stability is re-established. This pattern - and the broader phenomenon of plateau before the criterion is met - is covered in detail in the Wilson's T3 protocol guide.

The three-week completion criterion reflects an operational reality: the HPT axis needs extended suppression of endogenous T4 production to allow full reverse T3 clearance. Shorter periods of target temperature achievement do not reliably predict that the system is ready to resume endogenous production without regression.

The Taper Schedule: Mirror of the Titration Up

Once the three-week completion criterion is met, the research-community taper schedule is a structural mirror of the up-titration: reduce by 7.5 mcg per dose, every one to three days, until off.

This means that a research subject who reached their target dose at 75 mcg twice daily would taper from 75 mcg to 67.5 mcg at both doses, hold for one to three days, then drop to 60 mcg, continue in 7.5 mcg steps down through 52.5 mcg, 45 mcg, 37.5 mcg, 30 mcg, 22.5 mcg, 15 mcg, 7.5 mcg, and then off. A subject who reached target at a lower dose - say, 45 mcg twice daily - follows the same step structure from their own peak dose downward.

The rationale for this graduated reduction is straightforward: the HPT axis needs time at each lower dose to begin recovering endogenous T3 production incrementally. When exogenous T3 is high, TSH is suppressed and the thyroid's own T3 output is minimal. As the exogenous dose drops, the TSH suppression begins to lift - but TSH recovery lags by days to weeks, and thyroid T3 production re-establishes itself gradually rather than snapping back immediately.

A faster taper - dropping multiple steps at once, or stopping abruptly - creates a situation where the body suddenly lacks both the exogenous T3 that was supporting temperature and the endogenous T3 production that was suppressed during the protocol. The resulting gap in total T3 availability produces the classic withdrawal pattern: temperature falls, fatigue returns, cold intolerance worsens, and weight can begin to increase. Research subjects who have tapered too quickly consistently report that these symptoms are indistinguishable from a return of their pre-protocol presentation. Whether the underlying condition has returned or whether the taper was simply too fast to allow HPT axis recovery to keep pace is not immediately determinable from symptoms alone.

The one-to-three-day hold between steps gives the HPT axis the opportunity to start compensating before the next reduction. Some research subjects find that holding for a full three days at each step - rather than moving every one to two days - produces a smoother taper experience with fewer withdrawal-type symptoms. The research-community general guidance is to err on the side of slower rather than faster, since the cost of a slower taper is only time, whereas the cost of a taper that moves too fast is either symptom return or the need to re-enter the protocol.

The total duration of the taper phase depends on the peak dose and the step pace chosen. A subject tapering from 75 mcg in 7.5 mcg steps at two to three days per step completes the taper in roughly three to four weeks. A subject who opts for full three-day holds at each step of the same range takes approximately four to five weeks.

The Pharmacokinetic Argument: Why Sustained-Release Tapers Cleaner

Research subjects who have used immediate-release T3 (liothyronine tablets, Cytomel) for a protocol and then attempt to taper face a pharmacokinetic problem that SR-T3 does not create.

Immediate-release T3 produces a serum profile with sharp peaks and rapid falloffs. After each dose, serum T3 rises steeply within two to four hours, then declines toward baseline over the next four to six hours. When a dose is reduced in the taper - from, say, 45 mcg to 37.5 mcg - the new lower peak is reached at the scheduled dosing time, but in between doses, serum T3 may fall further toward baseline before the next dose restores it. As doses get smaller during the taper, the inter-dose troughs deepen. The result is a sawtooth serum curve where the declining averages are accompanied by increasingly pronounced inter-dose fluctuations. The body experiences these fluctuations as signal instability, and temperature tracking becomes difficult to interpret - is a temperature reading low because the dose has dropped appropriately, or because it was taken during a trough? Research subjects consistently report that immediate-release taper experiences are choppy, with variable symptom intensity depending on where in the dosing cycle they happen to be measured or how they happen to feel.

SR-T3 resolves this structurally. Because sustained-release capsules dissolve over eight to twelve hours, each dose produces a flat, sustained elevation rather than a sharp peak. When the dose is reduced in a taper step, the new lower sustained level is reached smoothly from the prior higher sustained level - without a serum gap, without a trough, without the sawtooth fluctuation that immediate-release creates. Each step of the taper represents a genuine reduction in sustained serum T3 exposure, and the transition between adjacent steps is gradual rather than interrupted. Research subjects consistently report cleaner taper experiences on SR-T3: symptoms remain stable as doses reduce, and temperature tracking continues to be reliable as the primary indicator of whether HPT axis recovery is keeping pace.

This pharmacokinetic advantage is the core reason the Wilson's WT3 protocol specifies SR-T3 rather than immediate-release for all protocol phases, including the taper. The sustained-release T3 complete guide covers the pharmacokinetics in full. For research subjects investigating the SR-T3 formulation used in this protocol, the Wilson's SR-T3 Combo Kit is the reference product.

What to Monitor During Weaning

Temperature monitoring during the taper is the primary data source for evaluating whether the HPT axis is recovering at a pace that matches the dose reduction schedule.

Oral body temperature should be measured at the same three daily timepoints used throughout the protocol: mid-morning, mid-afternoon, and early evening. The daily average is the tracking metric. During a clean taper, the daily average holds near the achieved target temperature even as the exogenous dose declines. If the average begins to fall - particularly if it drops more than 0.3 to 0.5 degrees Fahrenheit below the three-week target average - that signals that endogenous T3 production is not keeping pace with the exogenous reduction, and a dose hold or slower step pace may be warranted.

Resting heart rate is a secondary indicator. During the protocol's active phase, resting heart rate is commonly tracked as a sign of systemic T3 activity - rising T3 generally produces a modest increase in resting heart rate. During the taper, a falling resting heart rate that tracks below the subject's baseline (pre-protocol) resting heart rate can indicate that total T3 availability is dropping faster than the temperature alone suggests. Heart rate normalization within the pre-protocol range is expected and appropriate; a marked fall below baseline deserves attention.

Symptom diary entries during the taper serve two purposes. First, they provide real-time signal about whether the taper pace is producing withdrawal-pattern symptoms. Fatigue, cold intolerance, cognitive difficulty, or mood changes that emerge acutely at a taper step suggest the HPT axis has not yet adequately compensated. Holding at the current dose for additional days before the next step often resolves these symptoms as the axis catches up. Second, the symptom diary creates a record for evaluating the post-taper outcome - whether the improvements achieved during the protocol are maintained, partially maintained, or lost following taper completion.

Lab monitoring during the taper itself is generally limited. TSH during active exogenous T3 use remains suppressed and does not provide useful real-time feedback during the taper steps. Labs are typically most informative at four to six weeks after the final taper dose, once the HPT axis has had time to recover to a measurable equilibrium. Immediate post-taper TSH values lag the actual recovery state by weeks and are commonly misleading.

When Endogenous T3 Production Doesn't Return

Not every taper ends with a fully recovered HPT axis maintaining the protocol's achieved temperature. Research-community observation has defined three distinct post-protocol patterns.

Pattern A: Full recovery. The research subject completes the taper and body temperature remains at or near 98.6°F at the four-to-six-week post-taper follow-up. The HPT axis has re-established endogenous T3 production sufficient to maintain the reset metabolic set point without exogenous support. TSH at four to six weeks post-taper is within the normal reference range - not suppressed, not elevated - confirming that the axis is self-regulating. This is the protocol's intended outcome.

Pattern B: Temperature regression. Temperature holds near target in the days immediately following taper completion, then begins to fall over the following two to six weeks, returning toward or to the pre-protocol baseline. This pattern indicates that the HPT axis has not recovered adequate endogenous T3 output to independently maintain the reset temperature. It does not necessarily mean the protocol failed - some research subjects require two to three protocol cycles before the endogenous system fully consolidates the reset. The standard research-community response to this pattern is a four-to-six-week rest interval followed by re-entry into the Wilson's protocol at a starting dose calibrated to where the previous cycle's effective range was established.

Pattern C: Partial recovery. Temperature stabilizes post-taper above the pre-protocol baseline but below 98.6°F - often settling in the 97.8 to 98.2 range. The pre-protocol symptoms are partially improved: energy is better than before the protocol, cold intolerance is reduced but not resolved, cognitive function has partially improved. This represents a genuine partial success. The research subject has shifted their metabolic set point upward but has not achieved full normalization. Research subjects in this pattern commonly face a decision between re-entering the full cyclic protocol to attempt further reset versus transitioning to a low-dose maintenance SR-T3 input that sustains the partial improvement without the demands of a full protocol cycle. The maintenance approach - typically 15 to 25 mcg of SR-T3 - is often the practical choice for subjects who have already completed multiple cycles and find that each additional cycle produces diminishing incremental benefit.

All three patterns are informative. Pattern A confirms protocol completion. Patterns B and C redirect the research subject toward a defined next step rather than leaving the post-taper outcome ambiguous.

Taper-Adjustment Patterns

The Cofactor Status Check Before Tapering

Research-community practice among more experienced WT3 protocol subjects includes a cofactor reassessment before initiating the taper, on the premise that the taper's success depends on the HPT axis and downstream deiodinase activity recovering adequately once exogenous T3 is withdrawn.

Selenium is the most critical cofactor to evaluate. Both DIO1 and DIO2 are selenoproteins: their catalytic function depends on selenocysteine at the active site, which requires adequate selenium status. During the protocol's active phase, selenium's most visible role is in DIO2-mediated conversion - the step that isn't needed when T3 is supplied exogenously. But when exogenous T3 is withdrawn and the HPT axis resumes T4 production, DIO2 and DIO1 must operate efficiently to convert that T4 to T3. A research subject who is selenium-insufficient at taper initiation is tapering into a situation where endogenous conversion capacity is compromised before it is asked to do its job. Re-checking selenium status - or simply ensuring adequate selenium intake through selenomethionine or selenized yeast in the weeks leading into the taper - is a low-cost way to optimize conditions for HPT axis recovery.

Iron and ferritin matter for analogous reasons. Iron is a cofactor for thyroid peroxidase, the enzyme responsible for T4 synthesis in the thyroid gland. Low ferritin correlates with impaired thyroid hormone production and is associated with poor response to thyroid-related interventions generally. A research subject entering the taper with ferritin below 50 ng/mL is asking their HPT axis to resume T4 synthesis under an iron-limited condition. Addressing ferritin before the taper - or at minimum, identifying a low value so that post-taper regression can be attributed appropriately - is consistent with the broader research-community approach to cofactor optimization.

Cortisol status enters the conversation because elevated or dysregulated cortisol suppresses DIO2 activity and promotes DIO3-mediated reverse T3 production. A research subject whose cortisol axis is dysregulated at the time of taper may be generating reverse T3 more efficiently than they are converting T4 to T3, which undermines HPT axis recovery regardless of how well-executed the T3 taper schedule was. Research subjects who experienced significant adrenal stress during the protocol's active phase, or who have a history of HPA axis dysfunction, sometimes extend their pre-taper assessment to include a cortisol evaluation before initiating the step-down.

B-vitamins - particularly B2 (riboflavin) and B3 (niacinamide) - support cellular energy metabolism and the enzymatic pathways that underpin thyroid hormone utilization. Their role in the weaning context is less mechanistically specific than selenium or iron, but research subjects who have paid attention to broader micronutrient status throughout the protocol commonly extend that attention into the taper period.

The cofactor assessment before tapering is not a prerequisite - many research subjects taper successfully without a formal lab panel. Its value is in removing preventable confounders from the taper outcome, so that a regression or partial-recovery pattern can be attributed to its actual cause rather than to a cofactor limitation that was unknown and therefore unaddressed.

What Research Has and Hasn't Established

Established:

HPT axis suppression during exogenous T3 administration is well-documented in both clinical and research contexts. Studies of liothyronine use in thyroid cancer management, depression augmentation, and weight loss research consistently demonstrate that exogenous T3 suppresses TSH and reduces endogenous thyroid hormone production proportionally to dose and duration of use. HPT axis recovery following T3 discontinuation is also well-characterized in clinical pharmacology literature: TSH typically begins recovering within two to four weeks of discontinuing exogenous T3, with full normalization taking four to twelve weeks depending on dose and duration. Sustained-release T3 formulations produce a flatter pharmacokinetic curve than immediate-release liothyronine, a finding established in compounding pharmacokinetics research.

Hypothesis:

The specific 7.5 mcg per step, one-to-three-day hold taper schedule as optimal for Wilson's WT3 protocol weaning is a research-community convention rather than a parameter validated against alternative taper rates in controlled trials. The convention mirrors the up-titration schedule for structural consistency and is grounded in the general pharmacological principle that slow tapers reduce withdrawal risk - but the precise step size and hold duration have not been tested against, say, 5 mcg steps with seven-day holds, or 10 mcg steps with two-day holds, in a comparative design. The convention's widespread adoption in the research community reflects accumulated practitioner and self-reported subject experience rather than head-to-head evidence.

Not endorsed by mainstream endocrinology:

The Wilson's WT3 cyclic protocol - including its completion criterion, its taper structure, and the underlying Wilson's Temperature Syndrome diagnosis - operates outside mainstream endocrinology guidelines. Mainstream endocrinology does not recognize Wilson's Temperature Syndrome as a diagnosis, does not endorse the use of cyclic exogenous T3 for the restoration of metabolic set point, and does not recommend the 7.5 mcg taper schedule as a clinical protocol. Research subjects reviewing this material should situate it within the bioenergetic and functional-thyroid research-community context in which it was developed.

Frequently Asked Questions

How do I taper off Wilson's T3 protocol?

The research-community taper schedule reduces the dose by 7.5 mcg per dose every one to three days until reaching zero. This mirrors the up-titration schedule used to reach the target dose. Begin the taper only after sustaining a daily average temperature of 98.6°F for three consecutive weeks. Monitor temperature at three daily timepoints throughout the taper. If temperature falls significantly at any step, hold at the current dose for five to seven additional days before proceeding.

How long does Wilson's T3 weaning take?

Total taper duration depends on the peak dose and the step pace. A research subject tapering from 75 mcg twice daily in 7.5 mcg steps with two-to-three-day holds completes the taper in three to four weeks. A subject who elects full three-day holds at each step of the same range takes approximately four to five weeks. Lower peak doses produce shorter taper timelines. The taper should not be rushed to save time - the HPT axis recovery proceeds at its own pace, and a slower taper pace carries no meaningful downside beyond extended duration.

What if my temperature drops during weaning?

A temperature drop during the taper is a signal to pause, not to push through. Hold at the current dose for five to seven days and re-assess. In most cases, the HPT axis catches up to the current dose level and temperature stabilizes within that hold window, at which point the taper can resume at the next step. If temperature continues to fall despite the hold, consider returning to the prior dose for a week before re-attempting the step. A temperature fall during taper does not mean the protocol has failed - it means the HPT axis needs more time at the current dose level before absorbing the next reduction.

What if my symptoms come back after Wilson's protocol?

Symptom re-emergence in the weeks following taper completion is common and should be tracked in the context of both temperature and timing. If symptoms return alongside a temperature fall, the most likely explanation is incomplete HPT axis recovery - the body is not yet sustaining endogenous T3 production adequate to maintain the reset set point. A four-to-six-week rest interval followed by re-entry into the protocol is the standard research-community response. If symptoms return while temperature holds near 98.6°F, the cause is likely something other than the Wilson's-pattern metabolic dysregulation - cofactor status, adrenal function, or sleep disruption are common confounders worth investigating.

Can I re-enter Wilson's protocol if I relapse?

Yes. Research-community experience suggests that a significant proportion of subjects who complete a first cycle and subsequently regress go on to complete second or third cycles with improved or complete success. The protocol is explicitly designed as a cyclic intervention that can be repeated. After a post-taper regression, the standard guidance is a four-to-six-week rest interval before re-entering to allow the HPT axis to return to its equilibrium state (suppressed TSH from the prior cycle normalizes within this window). The starting dose for the subsequent cycle is typically calibrated based on where the effective range was established in the prior cycle.

Should I stay on a maintenance T3 dose after Wilson's?

Not as the default outcome. The protocol's design intent is full HPT axis recovery and independent maintenance of the achieved metabolic set point. However, research subjects who present with partial-recovery post-taper outcomes - stable temperature below 98.6°F with improved but not normalized symptoms - often find that a low-dose maintenance SR-T3 (15 to 25 mcg) sustains the partial improvement better than either re-entering the full cyclic protocol again or doing nothing. The maintenance dose is not a protocol failure; it reflects a realistic assessment of what the individual's endogenous system can sustain independently.

How do I know if my HPT axis recovered after Wilson's?

The primary indicator is body temperature. If daily average temperature remains at or above 98.6°F at four to six weeks post-taper without exogenous T3 support, the HPT axis is sustaining the reset set point. Lab confirmation - TSH within the normal reference range (not suppressed), free T3 within the upper third of the reference range - provides supporting evidence. Note that TSH lags weeks behind the actual recovery state: TSH at one to two weeks post-taper may still be suppressed or unmeasurably low even when the axis is recovering. Reliable TSH values are not obtained until four to six weeks after the final taper dose.

When do I lab-test TSH and free T3 after tapering?

The research-community standard is four to six weeks after the final dose. Testing earlier produces suppressed or low TSH values that do not reflect the true recovery state and are commonly misinterpreted as indicating hypothyroidism or failed axis recovery. Clinicians unfamiliar with the protocol's pharmacokinetics may recommend dose changes based on early post-taper labs that are simply reflecting normal HPT axis lag, not a pathological state. If labs are needed before four to six weeks for clinical reasons, the context of recent exogenous T3 discontinuation should be clearly communicated to the interpreting clinician.

Closing Note

The taper phase is where the Wilson's WT3 protocol delivers - or doesn't - on its core premise: that the metabolic thermostat can be permanently reset rather than continuously propped up by exogenous hormone. Most research subjects who reach the three-week completion criterion and execute a structured taper find that the protocol does what it was designed to do. Those who encounter regression or partial recovery have a defined set of next steps that the research community has documented and refined over years of accumulated experience.

For a comprehensive reference on the broader SR-T3 dosing landscape, troubleshooting side effects, and navigating the protocol across all phases, see the slow-release T3 dosing and troubleshooting complete guide. Research subjects exploring the SR-T3 formulation for the Wilson's protocol can review the Wilson's SR-T3 Combo Kit product reference, or browse the full research compound catalog for related compounds.